-->

Awards Registry

Marburg Virus Prophylactic Medical Countermeasure
Profile last edited on: 10/14/21

Program
STTR
Agency
CBD
Total Award Amount
$1,149,033
Award Phase
2
Principal Investigator
Larry Zeitlin
Activity Indicator

Location Information

Mapp Biopharmaceutical Inc

6160 Lusk Boulevard Suite C105
San Diego, CA 92121
   (858) 625-0335
   N/A
   www.mappbio.com
Multiple Locations:   
Congressional District:   52
County:   San Diego

Phase I

Phase I year
2018
Phase I Amount
$149,999
There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the context of operationalreadiness. Perhaps most significant is that vaccines require the host to develop an appropriate immune response. This response must be ofsufficient strength and also of appropriate specificity. Further, development of an immune response can take on the order of 1-6 monthsdepending upon how many boosts are required. Monoclonal antibodies (mAbs) offer an alternative that can address all of these limitations oftraditional vaccines. A controlled dose of a mAb(s) of known specificity and known protective activity can be administered, providinginstantaneous immunity to the Warfighter. With the use of well-characterized point mutations to the constant region of a mAb, providing 6-12months of protection should be feasible. The goal of this overall effort is to develop a mAb-based intramuscularly administered vaccinealternative for the Warfighter that would confer immediate immunity for 6-12 months.

Phase II

Phase II year
2020 (last award dollars: 2020)
Phase II Amount
$999,034
There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operational readiness. One of the most significant limitations is that vaccines rely on the host to develop an appropriate immune response. In order to confer immunity, this endogenous immune response must be of sufficient strength and also of appropriate specificity. Further, immunity can take on the order of 1-6 months to fully develop. Monoclonal antibodies (mAbs) offer an alternative that can directly address all of these limitations associated with traditional vaccines. A controlled dose of a mAb(s) of known specificity and known protective activity can be administered to provide instantaneous immunity to the Warfighter. Through the use of wellcharacterized point mutations, the already long serum half-life of an IgG1, can be dramatically extended. The goal of this effort is to develop a mAb-based intramuscularly administered vaccine alternative for the Warfighter that would confer immediate immunity for 6-12 months against aerosolized Marburg virus.